Holen Sie sich die Stockscreener-App
1.6675
6.37%
0.0975
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.57
Offen:
$1.57
24-Stunden-Volumen:
1.20M
Relative Volume:
0.59
Marktkapitalisierung:
$605.97M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-2.0844
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
+27.48%
1M Leistung:
+35.77%
6M Leistung:
+51.82%
1J Leistung:
+74.50%
1-Tages-Spanne:
$1.5501
$1.68
1-Wochen-Bereich:
$1.33
$1.83
52-Wochen-Spanne:
$0.2836
$1.83
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.6675 | 570.54M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.10 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.00 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
866.15 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.18 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.56 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) - Yahoo Finance
Lexicon Pharmaceuticals Rings the Closing Bell - Nasdaq
Risk Report: Can Lexicon Pharmaceuticals Inc reach all time highs this year - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Lexicon Pharma spikes after FDA feedback on pain drug - MSN
Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Shows High-Growth Momentum with Strong Technical and Fundamental Trends - Chartmill
Biopharma’s 30-year run: Lexicon to ring Nasdaq closing bell - Stock Titan
Downgrade Watch: How does Lexicon Pharmaceuticals Inc compare to its peersJuly 2025 Pullbacks & Safe Entry Trade Reports - baoquankhu1.vn
Lexicon rebounds on FDA nod for phase III non-opioid pain drug trial - BioWorld MedTech
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward - Seeking Alpha
Lexicon Pharmaceuticals (NASDAQ:LXRX) Reaches New 52-Week HighHere's Why - MarketBeat
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st
Lexicon Pharmaceuticals (NASDAQ:LXRX) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Lexicon Pharmaceuticals Boosts Outlook with Strategic Moves - StocksToTrade
Lexicon Pharmaceuticals (LXRX) Soars on Positive FDA Meeting Out - GuruFocus
Lexicon Pharma rises on FDA views on pain drug (LXRX:NASDAQ) - Seeking Alpha
Lexicon (LXRX) Receives FDA Green Light for Phase 3 Trials on Pi - GuruFocus
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain - manilatimes.net
Lexicon Pharmaceuticals Advances Pilavapadin to Phase 3 Development for Diabetic Peripheral Neuropathic Pain After FDA Meeting - Quiver Quantitative
Lexicon Pharmaceuticals announces successful end-of-phase 2 meeting with FDA for pilavapadin in the treatment of diabetic peripheral neuropathic pain - marketscreener.com
Lexicon Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA For Pilavapadin In The Treatment Of Diabetic Peripheral Neuropathic Pain - TradingView
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - Sahm
New UAE heart failure drug from Viatris targets fewer deaths, hospital trips - Stock Titan
Is Lexicon Pharmaceuticals Inc. stock a bargain at current levelsQuarterly Profit Report & Free Community Consensus Stock Picks - bollywoodhelpline.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) delivers shareholders notable 99% return over 1 year, surging 17% in the last week alone - simplywall.st
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.2% HigherTime to Buy? - MarketBeat
Lexicon flags $10 mln Novo Nordisk milestone and 2026 NDA plans - MSN
Aug PreEarnings: Will Lexicon Pharmaceuticals Inc. stock deliver long term returnsQuarterly Market Summary & Expert Approved Momentum Trade Ideas - Bộ Nội Vụ
Published on: 2026-01-13 21:48:56 - Bộ Nội Vụ
Lexicon Pharmaceuticals Publishes Relief is Possible, Ensuring Access to Effective Treatments for Chronic Pain - marketscreener.com
Lexicon Pharmaceuticals provides a business and pipeline update at the 44th annual J.P. Morgan healthcare conference - marketscreener.com
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Experimental heart, diabetes and pain drugs move ahead at Lexicon - Stock Titan
Published on: 2026-01-10 20:09:17 - ulpravda.ru
Lexicon Pharmaceuticals Releases White Paper on Addressing Chronic Pain with Non-Opioid Treatments Following Stakeholder Roundtable - Quiver Quantitative
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Will Lexicon Pharmaceuticals Inc. stock maintain growth storyAnalyst Downgrade & Fast Gain Stock Tips - Улправда
Making Medical Innovation Matter To Patients With Simplified Trial Design - Clinical Leader
Is Lexicon Pharmaceuticals Inc. stock cheap at current valuationTrade Performance Summary & Growth-Oriented Investment Plans - Улправда
Market Rankings: Can Lexicon Pharmaceuticals Inc. stock continue upward trendMarket Performance Recap & Scalable Portfolio Growth Ideas - ulpravda.ru
Is Lexicon Pharmaceuticals Inc. stock resilient to inflationJuly 2025 PostEarnings & Real-Time Buy Signal Notifications - Улправда
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals Inc Stock Analysis and ForecastInstitutional Buying Trends & Calculate Profit Targets With AI Accuracy - earlytimes.in
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Aug Update: Will Lexicon Pharmaceuticals Inc stock outperform Dow Jones index2025 Big Picture & Low Drawdown Trading Strategies - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Is Using Debt Safely - 富途牛牛
Profit Recap: Can Lexicon Pharmaceuticals Inc stock continue upward trendRisk Management & Free Daily Entry Point Trade Alerts - moha.gov.vn
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Cross Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 48%, while individual investors hold 27% - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE) - The Globe and Mail
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.16%
0.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):